JP2002504491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002504491A5 JP2002504491A5 JP2000532434A JP2000532434A JP2002504491A5 JP 2002504491 A5 JP2002504491 A5 JP 2002504491A5 JP 2000532434 A JP2000532434 A JP 2000532434A JP 2000532434 A JP2000532434 A JP 2000532434A JP 2002504491 A5 JP2002504491 A5 JP 2002504491A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide analog
- residue
- residues
- chain
- human insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2815698A | 1998-02-23 | 1998-02-23 | |
| US09/028,156 | 1998-02-23 | ||
| PCT/US1999/003915 WO1999042482A1 (en) | 1998-02-23 | 1999-02-23 | Methods for treatment of diabetes using peptide analogues of insulin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002504491A JP2002504491A (ja) | 2002-02-12 |
| JP2002504491A5 true JP2002504491A5 (cg-RX-API-DMAC7.html) | 2006-03-23 |
Family
ID=21841884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000532434A Pending JP2002504491A (ja) | 1998-02-23 | 1999-02-23 | インスリンのペプチドアナログを使用した糖尿病の処置のための方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6197926B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1056776A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002504491A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20010041238A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1241942C (cg-RX-API-DMAC7.html) |
| AP (1) | AP2000001888A0 (cg-RX-API-DMAC7.html) |
| AU (1) | AU741037B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR9908178A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2321929A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA003944B1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0100928A3 (cg-RX-API-DMAC7.html) |
| ID (1) | ID26788A (cg-RX-API-DMAC7.html) |
| IL (1) | IL137904A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20004198L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ506447A (cg-RX-API-DMAC7.html) |
| OA (1) | OA11453A (cg-RX-API-DMAC7.html) |
| PL (1) | PL342517A1 (cg-RX-API-DMAC7.html) |
| SK (1) | SK12412000A3 (cg-RX-API-DMAC7.html) |
| TR (1) | TR200003048T2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999042482A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562942B1 (en) * | 1999-02-23 | 2003-05-13 | Neurocrine Biosciences, Inc. | Methods for treatment of diabetes using peptide analogues of insulin |
| CN1125081C (zh) * | 1999-09-08 | 2003-10-22 | 中国科学院上海生物化学研究所 | 重组天然和新型人胰岛素及其制备方法 |
| US7462486B2 (en) * | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
| CA2408935A1 (en) * | 2000-05-12 | 2001-11-15 | Halina Offner | Method of treating immune pathologies with low dose estrogen |
| US20020103131A1 (en) * | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| US20040138116A1 (en) * | 2002-08-30 | 2004-07-15 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
| US20070172453A1 (en) * | 2002-08-30 | 2007-07-26 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
| ZA200502613B (en) | 2002-10-10 | 2006-10-25 | Yeda Res & Dev | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
| WO2004110373A2 (en) * | 2003-06-02 | 2004-12-23 | Mercia Pharma, Inc. | Therapeutic vaccine compositions for the treatment of type 1 diabetes |
| US8053197B2 (en) * | 2004-07-30 | 2011-11-08 | Oregon Health & Science University | Methods for detecting and treating autoimmune disorders |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| BRPI0907371A2 (pt) | 2008-01-09 | 2015-11-24 | Sanofi Aventis Deutschland | derivados de insulina com um perfil de tempo-ação muito retardado |
| DE102008003566A1 (de) * | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| US8481485B2 (en) * | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| WO2010080609A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| US12370251B2 (en) | 2009-11-05 | 2025-07-29 | Mercia Pharma, Inc. | Adjuvanted nanoparticulate influenza vaccine |
| CA2780043C (en) | 2009-11-13 | 2019-01-29 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
| US20110311536A1 (en) * | 2010-06-11 | 2011-12-22 | Dana-Farber Cancer Institute, Inc. | Prevention of type 1 diabetes by treg vaccination with an insulin mimetope |
| US8940860B2 (en) | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
| CA2803164C (en) | 2010-06-24 | 2018-08-21 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| SG187904A1 (en) | 2010-08-30 | 2013-04-30 | Sanofi Aventis Deutschland | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| WO2013096386A1 (en) | 2011-12-20 | 2013-06-27 | Indiana University Research And Technology Corporation | Ctp-based insulin analogs for treatment of diabetes |
| JP6387008B2 (ja) | 2012-09-26 | 2018-09-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリンアナローグダイマー |
| WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| EP3197912B1 (en) | 2014-09-24 | 2023-01-04 | Indiana University Research & Technology Corporation | Lipidated amide-based insulin prodrugs |
| SI3229828T1 (sl) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| CN111925420B (zh) * | 2019-12-11 | 2022-04-01 | 山东大学 | 一种多肽作为嗅觉受体Olfr109激动剂配体的应用 |
| USD1043348S1 (en) * | 2021-09-24 | 2024-09-24 | H.J. Heinz Company Brands Llc | Bottle |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| US5559094A (en) * | 1994-08-02 | 1996-09-24 | Eli Lilly And Company | AspB1 insulin analogs |
| US5594100A (en) * | 1995-02-22 | 1997-01-14 | Regents Of The University Of Colorado | Epitope for prevention of type I diabetes |
| AU6299596A (en) * | 1995-06-30 | 1997-02-05 | Novo Nordisk A/S | Prevention of a disease having the characteristics of diabetes |
-
1999
- 1999-02-23 CN CNB998042765A patent/CN1241942C/zh not_active Expired - Fee Related
- 1999-02-23 US US09/255,668 patent/US6197926B1/en not_active Expired - Fee Related
- 1999-02-23 NZ NZ506447A patent/NZ506447A/xx unknown
- 1999-02-23 EP EP99908385A patent/EP1056776A1/en not_active Withdrawn
- 1999-02-23 CA CA002321929A patent/CA2321929A1/en not_active Abandoned
- 1999-02-23 HU HU0100928A patent/HUP0100928A3/hu unknown
- 1999-02-23 SK SK1241-2000A patent/SK12412000A3/sk unknown
- 1999-02-23 ID IDW20001917A patent/ID26788A/id unknown
- 1999-02-23 JP JP2000532434A patent/JP2002504491A/ja active Pending
- 1999-02-23 KR KR1020007009330A patent/KR20010041238A/ko not_active Abandoned
- 1999-02-23 PL PL99342517A patent/PL342517A1/xx not_active Application Discontinuation
- 1999-02-23 AU AU27831/99A patent/AU741037B2/en not_active Ceased
- 1999-02-23 EA EA200000872A patent/EA003944B1/ru not_active IP Right Cessation
- 1999-02-23 IL IL13790499A patent/IL137904A0/xx unknown
- 1999-02-23 BR BR9908178-4A patent/BR9908178A/pt not_active IP Right Cessation
- 1999-02-23 WO PCT/US1999/003915 patent/WO1999042482A1/en not_active Ceased
- 1999-02-23 AP APAP/P/2000/001888A patent/AP2000001888A0/en unknown
- 1999-02-23 TR TR2000/03048T patent/TR200003048T2/xx unknown
-
2000
- 2000-08-22 NO NO20004198A patent/NO20004198L/no unknown
- 2000-08-22 OA OA1200000229A patent/OA11453A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002504491A5 (cg-RX-API-DMAC7.html) | ||
| EP0528312A3 (en) | Cyclic peptides and use thereof | |
| HUP0100928A2 (hu) | Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| AU2003264514A8 (en) | Wt1 substitution peptides | |
| PH12012502372A1 (en) | Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same | |
| GB9930882D0 (en) | GLP-2 formulations | |
| ATE402957T1 (de) | Analoge des menschlichen interferon-alpha mit niedriger toxizität | |
| JP2002509854A5 (cg-RX-API-DMAC7.html) | ||
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| DK0482013T3 (da) | Ikke-glycolyserede humant interleukin-3 analoge proteiner | |
| CA2208274A1 (en) | Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes | |
| MX9703642A (es) | Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana. | |
| AU2002330289A1 (en) | Preparation of a therapeutic composition | |
| WO2004009625A3 (en) | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES | |
| IL102346A0 (en) | Cysteine depleted il-6 muteins | |
| NZ508816A (en) | Bactericidal/permeability-increasing protein (BPI) deletion analogs | |
| DE60323634D1 (de) | Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16 | |
| DE69636052D1 (de) | Mpl-liganden analoga | |
| WO2003099849A3 (en) | Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy | |
| DE60036199D1 (de) | Proteaseresistente flint-analoge | |
| JP2004505616A5 (cg-RX-API-DMAC7.html) | ||
| WO2003097677A3 (fr) | Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c | |
| AU1464488A (en) | Human rhinovirus peptides | |
| ES2146555B1 (es) | Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y/o polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobresfuerzo fisico. | |
| DK119391A (da) | Humaninsulinanaloger |